微芯生物
(688321)
| 流通市值：70.51亿 | | | 总市值：70.51亿 |
| 流通股本：4.08亿 | | | 总股本：4.08亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 162,263,736.11 | 657,949,379.86 | 481,115,043.66 | 302,160,509.05 |
| 营业收入 | 162,263,736.11 | 657,949,379.86 | 481,115,043.66 | 302,160,509.05 |
| 二、营业总成本 | 181,685,156.93 | 735,520,875.8 | 519,910,892.74 | 336,896,673 |
| 营业成本 | 23,293,165.08 | 87,468,810.33 | 59,774,529.51 | 36,516,344.47 |
| 税金及附加 | 1,981,437.76 | 8,390,243.74 | 6,242,934.33 | 4,040,633.18 |
| 销售费用 | 76,517,207.44 | 330,796,358.52 | 236,830,428.49 | 149,709,739.04 |
| 管理费用 | 21,565,663.38 | 81,060,337.57 | 55,554,857.19 | 36,692,834.36 |
| 研发费用 | 52,906,135.89 | 213,517,781.37 | 147,574,384.7 | 102,214,756.98 |
| 财务费用 | 5,421,547.38 | 14,287,344.27 | 13,933,758.52 | 7,722,364.97 |
| 其中:利息费用 | 9,883,208.1 | 34,248,263.99 | 25,616,405.52 | 16,654,415.24 |
| 其中:利息收入 | 4,666,965.7 | 18,149,722.83 | -13,150,188.74 | 8,200,512.44 |
| 加:公允价值变动收益 | 46,849.32 | 106,925 | 85,095.89 | 810,369.87 |
| 加:投资收益 | -4,951,274.87 | -21,707,957.3 | -15,060,898.93 | -10,911,857.69 |
| 资产处置收益 | - | 234.5 | 234.5 | 234.5 |
| 资产减值损失(新) | - | -90,066,807.59 | - | - |
| 信用减值损失(新) | 131,571.31 | 2,686,952.37 | 3,167,484.13 | 2,301,758.3 |
| 其他收益 | 5,597,129.24 | 8,049,355.63 | 5,706,052.92 | 5,188,279.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -18,597,145.82 | -178,502,793.33 | -44,897,880.57 | -37,347,379.15 |
| 加:营业外收入 | 7,823.9 | 82,469,219.44 | 641,925.75 | 610,884.96 |
| 减:营业外支出 | 7,369.41 | 678,314.37 | 634,561.47 | 309,293.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -18,596,691.33 | -96,711,888.26 | -44,890,516.29 | -37,045,788.02 |
| 减:所得税费用 | 557,981.38 | 17,858,712.07 | 6,194,423.54 | 3,960,610.89 |
| 六、净利润 | -19,154,672.71 | -114,570,600.33 | -51,084,939.83 | -41,006,398.91 |
| 持续经营净利润 | -19,154,672.71 | -114,570,600.33 | -51,084,939.83 | -41,006,398.91 |
| 归属于母公司股东的净利润 | -19,154,672.71 | -114,570,600.33 | -51,084,939.83 | -41,006,398.91 |
| (一)基本每股收益 | -0.05 | -0.28 | -0.13 | -0.1 |
| (二)稀释每股收益 | -0.05 | -0.28 | -0.13 | -0.1 |
| 八、其他综合收益 | -81,678.3 | 754,998.1 | -503,438.33 | 368,462.32 |
| 归属于母公司股东的其他综合收益 | -81,678.3 | 754,998.1 | -503,438.33 | 368,462.32 |
| 九、综合收益总额 | -19,236,351.01 | -113,815,602.23 | -51,588,378.16 | -40,637,936.59 |
| 归属于母公司股东的综合收益总额 | -19,236,351.01 | -113,815,602.23 | -51,588,378.16 | -40,637,936.59 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-31 | 2024-08-16 |
| 审计意见(境内) | | 标准无保留意见 | | |